ReviewTranslational lung cancer research2015
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.
Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.BMC medical imaging · 2017Pooled it
- Design, in silico studies and biological evaluation of novel chalcones tethered triazolo[3,4-a]isoquinoline as EGFR inhibitors targeting resistance in non-small cell lung cancer.Scientific reports · 2024Article
- Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives.Journal of thoracic disease · 2024Review
- The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for DruggableInternational journal of molecular sciences · 2024Article
- Article
- Multiple mutations in theTranslational lung cancer research · 2022Review
- Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients.Cancers · 2022Article
- Optimizing the clinical management ofTranslational lung cancer research · 2022Review
- Circular RNA circ_0061140 accelerates hypoxia-induced glycolysis, migration, and invasion in lung adenocarcinoma through the microRNA-653/hexokinase 2 (HK2) axis.Bioengineered · 2022Article
- Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.Nature biomedical engineering · 2022Review
- EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.Nature reviews. Clinical oncology · 2022Review
- Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma.Journal of personalized medicine · 2021Review
- ECMarker: interpretable machine learning model identifies gene expression biomarkers predicting clinical outcomes and reveals molecular mechanisms of human disease in early stages.Bioinformatics (Oxford, England) · 2021Article
- Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma.Scientific reports · 2021Article
- Testing forOncoTargets and therapy · 2021Review
- A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.PloS one · 2021Article
- Detection of carcinoma in serous effusions: a review.American journal of cancer research · 2021Review
- Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.Translational oncology · 2020Article
- CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.BMC cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatic mutational profiling in cancer has revolutionized the practice of clinical oncology. The discovery of driver mutations in non-small cell lung cancer (NSCLC) is an example of this. Molecular testing of lung adenocarcinoma is now considered standard of care and part of the diagnostic algorithm. This article provides an overview of the workflow of molecular testing in a clinical diagnostic laboratory discussing in particular novel assays that are currently in use for somatic mutation detection in NSCLC focussing on epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK), ROS1 and RET rearrangements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.